Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05058443

Denosumab and Osteoporotic Vertebral Compression Fracture

Denosumab Protects Bone Loss and Function in Patients With Osteoporotic Vertebral Compression Fracture After Percutaneous Vertebroplasty: a Randomized Placebo-controlled Clinical Trial

Sponsor: Shenzhen People's Hospital

Conditions Osteoporotic Vertebral Compression Fracture

Interventions Denosumab 60 mg/ml [Prolia] Placebo

Updated 6 times since 2021 Last updated: Feb 18, 2023 Started: Jan 6, 2020 Primary completion: Aug 5, 2022 Completion: Aug 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05058443, this PHASE2/PHASE3 trial focuses on Osteoporotic Vertebral Compression Fracture and remains completed. Sponsored by Shenzhen People's Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Sep 2022 — Mar 2023 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Oct 2021 — Jul 2022 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen People's Hospital

Data source: Shenzhen People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China